Literature DB >> 3575649

Pathology of delayed radiation brain damage: an experimental canine model.

J K Tiller-Borcich, J R Fike, T L Phillips, R L Davis.   

Abstract

Delayed radiation damage of normal brain can be a devastating complication of radiation therapy and generally occurs months to years after the initiation of therapy. Primarily restricted to the white matter, radiation damage is characterized by a number of histopathologic changes including coagulation necrosis, vascular alterations with fibrinoid necrosis, edema, and demyelination. Normal dogs were exposed to either 10, 15, or 30 Gy of X rays to a single hemisphere and the gross and histopathologic changes were evaluated qualitatively. A spectrum of changes was observed ranging from white matter edema to extensive white matter necrosis, and the extent, location, and type of damage were dependent upon radiation dose. Histopathologic changes were separated into three major categories based on the character and size of the lesions, with the most severe changes being similar to the types of changes described in human patients who have developed delayed radiation necrosis. Less severe forms of damage such as multifocal, sometimes confluent areas of microscopic necrosis with spongiotic borders and edema with severe axonal swelling were also observed. These latter changes are not well recognized as being due to radiation. The findings of this study also indicate that many of the changes ascribed to combined treatment with methotrexate and radiation in humans are induced in the normal dog brain by radiation alone. The results of his study show that the dog is a suitable model of the human brain for studying radiation brain injury and may be useful for investigation of drug-radiation interactions.

Entities:  

Mesh:

Year:  1987        PMID: 3575649

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  7 in total

1.  Development of a novel animal model to differentiate radiation necrosis from tumor recurrence.

Authors:  Sanath Kumar; Ali S Arbab; Rajan Jain; Jinkoo Kim; Ana C deCarvalho; Adarsh Shankar; Tom Mikkelsen; Stephen L Brown
Journal:  J Neurooncol       Date:  2012-03-10       Impact factor: 4.130

2.  White matter changes in breast cancer brain metastases patients who undergo radiosurgery alone compared to whole brain radiation therapy plus radiosurgery.

Authors:  Timothy B Stokes; Ajay Niranjan; Hideyuki Kano; Phillip A Choi; Douglas Kondziolka; L Dade Lunsford; Edward A Monaco
Journal:  J Neurooncol       Date:  2014-12-02       Impact factor: 4.130

3.  White matter changes on magnetic resonance imaging following whole-brain radiotherapy for brain metastases.

Authors:  Osamu Fujii; Kayoko Tsujino; Toshinori Soejima; Eisaku Yoden; Yukako Ichimiya; Kazuro Sugimura
Journal:  Radiat Med       Date:  2006-06

4.  Cranial irradiation leads to acute and persistent neuroinflammation with delayed increases in T-cell infiltration and CD11c expression in C57BL/6 mouse brain.

Authors:  Michael J Moravan; John A Olschowka; Jacqueline P Williams; M Kerry O'Banion
Journal:  Radiat Res       Date:  2011-07-25       Impact factor: 2.841

5.  Methotrexate-related multifocal axonopathy. Report of an autopsy case.

Authors:  M Shibutani; R Okeda; A Hori; H Schipper
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

6.  Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intra-arterial BCNU and irradiation: a pathological study.

Authors:  M K Rosenblum; J Y Delattre; R W Walker; W R Shapiro
Journal:  J Neurooncol       Date:  1989-09       Impact factor: 4.130

7.  Demonstrating a reduced capacity for removal of fluid from cerebral white matter and hypoxia in areas of white matter hyperintensity associated with age and dementia.

Authors:  Matthew MacGregor Sharp; Satoshi Saito; Abby Keable; Maureen Gatherer; Roxana Aldea; Nivedita Agarwal; Julie E Simpson; Stephen B Wharton; Roy O Weller; Roxana O Carare
Journal:  Acta Neuropathol Commun       Date:  2020-08-08       Impact factor: 7.801

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.